Epirubicin (Ellence)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. Inhibits DNA helicase activity, preventing enzymatic separation of double-stranded DNA.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 9/15/1999: Initial FDA approval "as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer."

Also known as

Synonyms
Alrubicin Anthracin Binarin Bioepicyna Crisabon
E.P.R Elvetium Ellence EPI EPI Cell Epidoxo
Epifil Epilem Epirubicin Epirubicina Microsules Epirubicine
Epirubicin Ebewe Epirubicine HCl PCH Epirubicin Hexal Epirubicin Hydrochloride Epizin
Epricin Eracin Famorubicin Farmorubicin Farmorubicin-RTU
Farmorubicina Farmorubicina CS Farmorubicina PFS / RTU Farmorubicin CS Farmorubicin DR
Farmorubicine Farmorubicine R.T.U. Farmorubicine RTU Farmorubicin HL Farmorubicin PFS
Farmorubicin RD Farmorubicin Solution Pharmorubicin CS Riboepi Rubifarm
Trav Epirubicin Vero Epirubicin

References